[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_431 

# __Development of drugs__

## Category to which it belongs

* [The challenges include reduced surgical education, loss of control, limited diagnostics, slow drug development, inadequate patient monitoring, and lack of drug therapy options.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_110.md)

## Closest similar item

* [Slow drug development](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_466.md)
* [Delayed drug development](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1801.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2724.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1602.md)
* [Identification of effective drug compounds](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_3045.md)
* [Lack of accessibility of pharmaceutical interventions in developing countries](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_727.md)
* [Lack of access to pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1158.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1146.md)
* [Missing information in existing drug ontologies](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_40.md)
* [Impact on healthcare systems and pharmaceutical industry](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1812.md)

## Description of the risk

Efforts are being made to develop effective drugs for the treatment of COVID-19.

## Property: has_RiskGBN

* [No](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_0.md)

## Property: has_RiskHealth

* [physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Property: has_RiskISO_Impact

* [Innovation, Creativity and research](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_2.md)

## Property: has_RiskISO_Purpose

* [Innovation, Creativity and research](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_8.md)

## Mitigations of this risk

* [Continued research and development of drugs for the treatment of COVID-19.](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_3066.md)
* [Drug development](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_599.md)

## Name of the risk

Limited treatment options and control measures without effective drugs.

## Stakeholders who can mitigate this risk

* [scientists](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_46.md)
* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)

## Articles mentionning the risk

* [Current knowledge of COVID-19: Advances, challenges and future perspectives](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_118.md)

## People affected by this risk

* [patients](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_31.md)
* [healthcare providers](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_121.md)

## Technologies linked to the risk

* [clinical trials](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_1961.md)
* [research on potential therapeutic options](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_1962.md)

## Property: has_RiskType

* [technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

